NEW YORK, Dec. 9, 2014 /PRNewswire/ -- S&P Capital
IQ (MHFI) announced today that it has commenced Factual Stock
Report coverage on SQI Diagnostics Inc.
SQI Diagnostics Inc. (TSXV:SQD; OTCQX:SQIDF) is a life sciences
and diagnostics company that develops and commercializes
proprietary technologies and products for advanced microarray
diagnostics. The company's proprietary microarray tests and fully
automated systems are designed to simplify protein and antibody
testing workflow, increase throughput, reduce costs and provide
excellent data quality.
SQI's multiplex tests and automated platforms together form a
tool for the design, development and execution of blood testing in
clinical trials for pharmaceutical and biotechnology companies
developing novel drugs, as well as for regulatory cleared in vitro
diagnostic (IVD) immunology testing done in reference
laboratories.
The company is commercializing its technology through two
principal and integrated lines of business. SQI's Diagnostic Tools
and Services (DTS) business is focused primarily on drug
development customers including pharmaceutical companies,
biotechnology companies and vaccine companies along with the
contract research organizations (CROs) that serve them. The company
believes that its custom microarray tests and automated diagnostic
platforms have the potential to change the way pharmaceutical
companies design and conduct their testing of biologically
important markers.
SQI's business model for this market segment is to provide its
customers comprehensive turnkey services including the initial
rapid design, development and validation of custom multiplex test
kits. The customer then contracts SQI to manufacture these custom
kits for purchase and use in their pre-clinical and clinical drug
trials, with testing conducted at the customer or its CRO. In some
cases, SQI can also provide sample analysis performed at the
company, as a service. The company says that its technology meets
or exceeds all FDA and European Medicines Agency (EMA) guidance for
immunogenicity and biosimilar test guidelines.
SQI is also advancing a pipeline of multiplexed IVD products
targeting protein and antibody biomarkers relevant to autoimmune
and other immunology diseases.
These tests are developed, validated and manufactured by the
company for direct marketing and sales to reference labs once
cleared by regulators such as the FDA. The company says that its
systems and multiplexing technologies enable many tests to be
completed in a single well of one of its consumable test kits at
low cost and with minimal labor requirements using SQI's
semi-automated or fully automated high-throughput systems.
SQI's lead IVD assay is its multiplexed Ig_plex Celiac DGP
Panel, which provides clinicians with a rapid tool to quantify the
levels of multiple key biomarkers associated with celiac
disease.
SQI has developed a range of analytical platforms that are
designed to meet the varying needs of its customers in both its DTS
and IVD markets.
The company's high-throughput sqidworks* (*Trademark) Diagnostic
Platform (sqidworks) is a fully automated microarray processing and
analytical instrument, primarily suited for high-volume reference
laboratories.
SQI's mid-range sqidlite* Bench-Top Diagnostic System (sqidlite)
offers laboratories of all sizes flexible, configurable, fully
automated workflow solutions for processing protein and antibody
multiplexed immunoassays in both its DTS and IVD markets.
The company's sqid-X* System is a semi-automated bench-top
platform that incorporates all of SQI's technology with the
exception of automated fluidics handling and is targeted at early
adopters; earlier stage, lower volume customers; and customers that
intend to complete custom assay development work at their
sites.
In November 2014, SQI Diagnostics
announced that it has received notice that the United States Food
and Drug Administration (FDA) has cleared the company to market its
proprietary Celiac Panel in the United
States (US). The company also announced that it that it has
expanded its existing commercial relationship with one of the
world's largest pharmaceutical companies.
In August 2014, the company
announced that it has entered into a Master Service Agreement to
contract with a UK-based company to automate their DNA-based
pathogen detection assays. During the initial phase of this
agreement, SQI Diagnostics will be paid to deliver an automated
working prototype of one of the customer's assays, operational on
SQI's sqidlite system. The initial phase is scheduled for
completion by mid-September 2014. It
is anticipated that other molecular diagnostic tests will be
commissioned in a separate agreement following successful
implementation of the initial phase.
SQI continues to focus on selling prototype products and
services in its DTS business to new customers and on converting
these evaluation projects to higher volume kit sales for use in
clinical trial programs. New customer generation efforts are
largely focused on pharmaceutical, biotech and vaccine companies
that currently use single-plex immunogenicity tests in their
product development activities, as well as the CROs that service
the immunogenicity testing needs of pharmaceutical companies.
S&P Capital IQ's Factual Stock Report coverage on SQI
Diagnostics Inc will also be accessible on an ongoing basis to the
investment community by scores of buy-side institutions and
sell-side firms that utilize S&P Capital IQ research and
information platforms daily. Millions of self-directed investors
also have access to the report via their e-brokerage accounts.
Please visit http://www.sqidiagnostics.com for additional
information.
About S&P Capital IQ's Factual Stock Reports
Currently profiling approximately 400 issuers, S&P Capital
IQ (MHFI) Factual Stock Reports increase market awareness of
issuers in the investment community with insightful commentary, key
statistics, and relevant corporate information. The Reports
provide factual research coverage about company fundamentals and
business prospects, thereby enabling information on the covered
companies to reach a wide spectrum of Buy and Sell-side investors.
Updated weekly with the latest pricing, trading volume, and other
data, the Reports also capture recent company developments, a
financial review, key operating information, industry and peer
comparisons, Street Consensus, performance charts, business
summary, fundamental data, and timely news stories. Coverage of
these reports is underwritten by the issuer, therefore S&P
Capital IQ does not offer investment opinions concerning the
advisability of investing in these stocks.
S&P Capital IQ Factual Stock Reports are produced separately
from any other analytic activity of S&P Capital IQ or related
organizations. S&P Capital IQ does not trade on its own
account.
About S&P Capital IQ
S&P Capital IQ, a part of McGraw Hill Financial (NYSE:MHFI),
is a leading provider of multi-asset class and real time data,
research and analytics to institutional investors, investment and
commercial banks, investment advisors and wealth managers,
corporations and universities around the world. S&P Capital IQ
provides a broad suite of capabilities designed to help track
performance, generate alpha, and identify new trading and
investment ideas, and perform risk analysis and mitigation
strategies. Through leading desktop solutions such as the S&P
Capital IQ, Global Credit Portal and MarketScope Advisor desktops;
enterprise solutions such as S&P Capital IQ Valuations; and
research offerings, including Leveraged Commentary & Data,
Global Markets Intelligence, and company and funds research,
S&P Capital IQ sharpens financial intelligence into the wisdom
today's investors need. For more information, visit
www.spcapitaliq.com.
In the United States, research
reports are prepared by Standard & Poor's Investment Advisory
Services LLC, a part of S&P Capital IQ and a registered
investment adviser with the U.S. Securities and Exchange
Commission. S&P Capital IQ provides a broad suite of
capabilities designed to help track performance, generate alpha,
and identify new trading and investment ideas, and perform risk
analysis and mitigation strategies.
About SQI Diagnostics Inc.
SQI Diagnostics is a life sciences and diagnostics company that
develops and commercializes proprietary technologies and products
for advanced microarray diagnostics. The Company's proprietary
microarray tests and fully-automated systems are designed to
simplify protein and antibody testing workflow, increase
throughput, reduce costs and provide excellent data quality. For
more information, please visit www.sqidiagnostics.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sp-capital-iq-initiates-coverage-on-sqi-diagnostics-inc-in-sp-capital-iq-factual-stock-reports-300007356.html
SOURCE S&P Capital IQ